Access to anti-retroviral drugs, male in Guyana

Guyana: Access to anti-retroviral drugs, male was 66.0% in 2024. ◆ Volatile

Latest (2024)
66.0%
Change on year
up 6.5%
World rank
80th
of 141 countries
All-time high
66.0%
in 2024
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, male in Guyana, 2000–2024

02040602000201220242000: 0 %2001: 0 %2002: 0 %2003: 3 %2004: 10 %2005: 22 %2006: 27 %2007: 31 %2008: 34 %2009: 37 %2010: 38 %2011: 41 %2012: 44 %2013: 46 %2014: 48 %2015: 50 %2016: 53 %2017: 57 %2018: 56 %2019: 59 %2020: 57 %2021: 59 %2022: 60 %2023: 62 %2024: 66 %

Source: UNAIDS estimates. Measured in %.

Analysis

Guyana recorded 66.0% for access to anti-retroviral drugs, male in 2024. That is the highest value across all 25 years on record.

Compared with earlier readings it is up 6.5% on the previous year and up 37.5% over ten years.

Over the whole period, access to anti-retroviral drugs, male in Guyana peaked at 66.0% in 2024 and was at its lowest, 0.0%, in 2000.

Guyana ranks 80th of 141 countries on this measure, in the middle of the range.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, male in Guyana, year by year

Annual values for Access to anti-retroviral drugs, male (%) in Guyana, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 3.0%
2004 10.0% +233.3%
2005 22.0% +120.0%
2006 27.0% +22.7%
2007 31.0% +14.8%
2008 34.0% +9.7%
2009 37.0% +8.8%
2010 38.0% +2.7%
2011 41.0% +7.9%
2012 44.0% +7.3%
2013 46.0% +4.5%
2014 48.0% +4.3%
2015 50.0% +4.2%
2016 53.0% +6.0%
2017 57.0% +7.5%
2018 56.0% -1.8%
2019 59.0% +5.4%
2020 57.0% -3.4%
2021 59.0% +3.5%
2022 60.0% +1.7%
2023 62.0% +3.3%
2024 66.0% +6.5%

Averages by decade

DecadeAverage LowestHighest Years
2000s 16.4% 0.0% 37.0% 10
2010s 49.2% 38.0% 59.0% 10
2020s 60.8% 57.0% 66.0% 5

Countries ranked near Guyana

  1. 78 Chad 67.0% compare
  2. 78 Mexico 67.0% compare
  3. 80 Cuba 66.0% compare
  4. 80 Slovakia 66.0% compare
  5. 83 Iraq 65.0% compare
  6. 83 Morocco 65.0% compare
  7. 83 Oman 65.0% compare
  8. 83 Serbia 65.0% compare

See the full ranking of 160 places →

More gender data for Guyana

All data for Guyana →

Frequently asked questions

What is access to anti-retroviral drugs, male in Guyana?
Access to anti-retroviral drugs, male in Guyana was 66.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, male recorded in Guyana?
The highest recorded value was 66.0% in 2024.
What is the lowest access to anti-retroviral drugs, male recorded in Guyana?
The lowest recorded value was 0.0% in 2000.
How does Guyana rank for access to anti-retroviral drugs, male?
Guyana ranks 80th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, male rising or falling in Guyana?
Over the last ten years it is up 37.5%. The long-run trend across the full record is volatile.
Where does this Guyana data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, male (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, male in Guyana. Statizoid, drawing on UNAIDS estimates. Retrieved 08 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/guyana/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/guyana/">Access to anti-retroviral drugs, male in Guyana</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, male (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,923 data points, 2000–2024
Last refreshed

The percentage of adult males living with HIV who are receiving antiretroviral therapy.